Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
January 03, 2017
> Therapeutic candidate IVA337 is a next generation PanPPAR agonist addressing all the relevant clinical and regulatory features of NASH
> NATIVE clinical study plans to enroll 225 patients in 12 European countries
> Headline results are expected mid-2018
Daix, France, January 3, 2017 – Inventiva, an emerging biopharmaceutical company developing innovative therapies notably to treat fibrosis, today announces the beginning of patient enrollment for its Phase IIb clinical trial (NATIVE – NASH Trial to Validate IVA337 Efficacy) evaluating the Company’s lead compound, IVA337, for the treatment of Non-Alcoholic Steatohepatitis (NASH). “Unlike other drugs targeting NASH, IVA337, a next generation PanPPAR agonist, addresses all the relevant clinical and regulatory features of this condition: steatosis, inflammation, ballooning and fibrosis.” said Pierre Broqua, co-founder and Chief Scientific Officer of Inventiva.
NASH is a severe and chronic form of non-alcoholic fatty liver disease that has become a leading cause to the need for liver transplantation. NASH affects over 30 million people in the United States1 , increases 5 to 10 fold the risk of liver related mortality and is expected to become the leading cause of liver transplantation by 2020. There are no pharmaceutical treatments currently approved and treatment options are limited to lifestyle changes, weight loss and or medical procedures, such as bariatric surgery.
NATIVE is a randomized, double-blind, placebo-controlled, multi-center, Phase IIb clinical trial in NASH patients. The study will investigate the safety and efficacy of two doses of IVA337 (800 and 1200 mg/day) over a 24-week period and will enroll up to 225 patients in 12 European countries. The primary endpoint will be based on histologically assessed improvement of the activity component of the SAF2 score combining inflammation and ballooning, without worsening of fibrosis.
“NASH is a highly prevalent condition with a significant unmet medical need,” said Prof Sven Francque of the Antwerp University Hospital, and one of the trial’s Principal Investigators. “The medical community is in search of a treatment that resolves NASH without worsening fibrosis. Based on the data generated in pre- clinical models, IVA337 has the potential to meet this objective. Therefore, we are excited to further evaluate IVA337 in this Phase IIb clinical trial.”
“We are very pleased with the progress so far and the positive feed-back received from regulatory agencies as well as from the clinicians involved in the study: we look forward to the full enrollment of this study in the second half of 2017” said Dr Jean-Louis Abitbol, Inventiva’s CMO.
IVA337 which has demonstrated anti-fibrotic properties in several tissues alongside good clinical tolerance is currently in a Phase IIb trial for the treatment of systemic sclerosis, another fibrotic disease with very high unmet medical needs. IVA337 has undergone a successful Phase IIa study in diabetic patients with improvements in markers of insulin resistance (HOMA-IR), and dyslipidemia (increase in circulating HDL cholesterol and decrease of circulating triglycerides). These clinical findings are extremely valuable as the physiopathology of NASH is intimately linked to obesity, IR and T2DM. Furthermore data generated in multiple relevant pre-clinical models demonstrated that IVA337 also positively impacts all hepatic lesions associated with NASH. In these pre-clinical studies, IVA337 significantly reduced steatosis, ballooning and inflammation, and reversed established liver fibrosis.
“This is a very important study in identifying a new treatment for NASH, a condition associated with increased mortality, with excess cardiovascular-, liver- and cancer-related deaths,” added Pierre Broqua. “Importantly, by measuring the efficacy of IVA337 on histological scores for ballooning and inflammation, the NATIVE study will evaluate the effects of IVA337 on the two components defining NASH resolution, a regulatory approved endpoint. The initiation of this study represents a critical milestone for our company as we continue to advance our diversified pipeline.”
1 Angulo et al. ;Hepatology 1999; 30(6):1356-62.; Minervini et al. ;J Hepatology 2009; 50:501–510
2 SAF is a scoring system to measure liver lesions that dissociates grade of steatosis, grade of activity, and stage of fibrosis thus enabling an easy comparison between biopsies and changes observed in paired biopsies during clinical trials.
Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.
Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.
Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.
Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.
There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.
Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.